תמיכה במטופלים

Summary of the ASH Conference

Staging autoimmune type 1 diabetes (T1D) allows for early identification, monitoring, and intervention¹

TZIELD is the first and only immunomodulator indicated to delay the onset of Stage 3 T1D in patients aged 8 years and older with Stage 2 T1D. In the TN-10 study, one 2-week course of TZIELD doubled the median time to Stage 3 onset compared to placebo⁵. The median follow-up time was 51 months. In the extended follow-up of the TN-10 study, the median time to Stage 3 onset was approximately 5 years with TZIELD versus approximately 2 years with placebo⁶. Choose proactive intervention, Treat appropriate stage 2 T1D patients with TZIELD today.

NIH & LSS Booklet